2019 annual results and business update
(WorldNews France)

Press release 2019 annual results and business update Operational facilities resolutely preparing for large series Gradual focus on the United States Reduction of losses, thanks in large part to commercial activities Covid-19likely to have an impact on timing, but teams remain operational Dijon, 26 March 2020 CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of combined drugs for use in emergency situations, is announcing its 2019 results and issuing a business update. Patrick Alexandre, CEO of Crossject, said: "2019 was a bumper year for the company. The contract signed with Desitin Pharma and the R&D...